Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of Orelabrutinib in Healthy Volunteers
NCT03189017Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) comparing ICP-022 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events up to 28 days. Started Jul 2017; status: completed.
02
Drugs
orelabrutinib
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03189017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189017.